Abstract
Parathyroid hormone (PTH) is the key endocrine factor regulating systemic Ca2+ homeostasis. Elevated levels of circulating PTH increase bone turnover and, depending on the duration of elevation, will result in net anabolic or catabolic effects on the skeleton. Secretion of PTH from the parathyroid glands is regulated by small changes in circulating levels of Ca2+ which are detected by a Ca2+ receptor on the surface of parathyroid cells. This G protein-coupled receptor is the primary molecular entity used by parathyroid cells to regulate secretion of PTH. As such, the Ca2+ receptor is a unique molecular target for new drugs capable of increasing or decreasing circulating levels of PTH. Compounds which activate the Ca2+ receptor are termed calcimimetics and they inhibit the secretion of PTH, a calcimimetic compound is in late stage clinical trials for the treatment of both primary and secondary hyperparathyroidism. Conversely, calcilytic compounds, which are Ca2+ receptor antagonists, stimulate secreti on of PTH, a calcilytic compound is in early clinical development for the treatment of osteoporosis.
Keywords: Pharmacological Regulation, Parathyroid Hormone, Calcimimetics, Calcilytics, HYPERPARATHYROIDISM, Osteodystrophy
Current Pharmaceutical Design
Title: Pharmacological Regulation of Parathyroid Hormone Secretion
Volume: 8 Issue: 23
Author(s): E. F. Nemeth
Affiliation:
Keywords: Pharmacological Regulation, Parathyroid Hormone, Calcimimetics, Calcilytics, HYPERPARATHYROIDISM, Osteodystrophy
Abstract: Parathyroid hormone (PTH) is the key endocrine factor regulating systemic Ca2+ homeostasis. Elevated levels of circulating PTH increase bone turnover and, depending on the duration of elevation, will result in net anabolic or catabolic effects on the skeleton. Secretion of PTH from the parathyroid glands is regulated by small changes in circulating levels of Ca2+ which are detected by a Ca2+ receptor on the surface of parathyroid cells. This G protein-coupled receptor is the primary molecular entity used by parathyroid cells to regulate secretion of PTH. As such, the Ca2+ receptor is a unique molecular target for new drugs capable of increasing or decreasing circulating levels of PTH. Compounds which activate the Ca2+ receptor are termed calcimimetics and they inhibit the secretion of PTH, a calcimimetic compound is in late stage clinical trials for the treatment of both primary and secondary hyperparathyroidism. Conversely, calcilytic compounds, which are Ca2+ receptor antagonists, stimulate secreti on of PTH, a calcilytic compound is in early clinical development for the treatment of osteoporosis.
Export Options
About this article
Cite this article as:
Nemeth F. E., Pharmacological Regulation of Parathyroid Hormone Secretion, Current Pharmaceutical Design 2002; 8 (23) . https://dx.doi.org/10.2174/1381612023393387
DOI https://dx.doi.org/10.2174/1381612023393387 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation in Alzheimer’s Disease
Current Alzheimer Research Gene-Gene and Gene-Environment Interaction on the Risk of Parkinson’s Disease
Current Aging Science Glycemic Control is Related to Cognitive Dysfunction in Elderly People with Type 2 Diabetes Mellitus in a Rural Chinese Population
Current Alzheimer Research Is α7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment?
Current Drug Targets Water Promoted One-pot Three-Step Synthesis of Novel N-Saccharin Isoxazolines/Isoxazoles Using KI/Oxone Under Ultrasonic Activation
Current Organic Chemistry Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Forceps: Still an Option?
Current Women`s Health Reviews Pharmacogenetics of Drug Transporters and Its Impact on the Pharmacotherapy
Current Topics in Medicinal Chemistry Current Trends in Drug Delivery System of Curcumin and its Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic:Toward Translational Research on VIP AND PACAP (Executive Editor: A. Arimura)]
Current Pharmaceutical Design Brain Inflammation Following Intracerebral Hemorrhage
Current Neuropharmacology Recombinant Human Semenogelin-1 (Sg1) and Sg1 (1-159) form Detergent Stable Amyloid like Aggregates in vitro
Protein & Peptide Letters Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Schizophrenia and Liver Dysfunction Caused by Portacaval Shunting
Current Psychiatry Reviews Preliminary Study on Nematocyst Types and Venom Isolation of Cassiopea andromeda Forskål, 1775 (Scyphozoa, Cnidaria) from Turkey
Central Nervous System Agents in Medicinal Chemistry Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer’s Disease
Current Medicinal Chemistry Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Insulin-Like Growth Factor-1 and its Derivatives: Potential Pharmaceutical Application for Ischemic Brain Injury
Recent Patents on CNS Drug Discovery (Discontinued)